✦ LIBER ✦

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528

✍ Scribed by Gadgeel, Shirish M.; Lew, Danika L.; Synold, Timothy W.; LoRusso, Patricia; Chung, Vincent; Christensen, Scott D.; Smith, David C.; Kingsbury, Laura; Hoering, Antje; Kurzrock, Razelle

Book ID: 121611399
Publisher: Springer
Year: 2013
Tongue: English
Weight: 400 KB
Volume: 72
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s00280-013-2297-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

364 The first-in-human, first-in-class s

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

✍ T. Shimizu; A.W. Tolcher; P. LoRusso; K. Papadopoulos; A. Patnaik; L. Smith; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB

A phase I dose escalation study of BIBW

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

✍ Eskens, F A L M; Mom, C H; Planting, A S T; Gietema, J A; Amelsberg, A; Huisman, 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 173 KB

93 POSTER Phase I study of daily oral AZ

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB